Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know

The American Journal of the Medical Sciences
Steven R FeldmanShahla Namak

Abstract

The introduction of biologics has revolutionized the treatment of immune-mediated diseases, but high cost and limited patient access remain hurdles, and some physicians are concerned that biosimilars are not similar enough. The purpose of this narrative review is to describe biosimilar safety, efficacy, nomenclature, extrapolation and interchangeability. In the United States, the Biologics Price Competition and Innovation Act created an abbreviated pathway for licensing of a biologic that is biosimilar to another licensed product (i.e., the reference product). This approval pathway differs from that of generic small-molecule drugs because biologics are too complex to be perfectly duplicated, and follows a process designed to demonstrate that any differences between the biosimilar and its reference product have no significant impact on safety and efficacy. The US approval process requires extensive analytical assessments, animal studies and clinical trials, assuring that biosimilar products provide clinical results similar to those of the reference product.

Citations

May 3, 2019·Expert Opinion on Drug Safety·Sree S KolliSteven R Feldman
Aug 24, 2018·Expert Opinion on Drug Metabolism & Toxicology·Michael S HeathSteven R Feldman
Aug 25, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Joseph S AleshakiSteven R Feldman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

American Society of Clinical Oncology Educational Book
Steven LemeryMartina Weise
Bulletin du cancer
Dominique Levêque
© 2022 Meta ULC. All rights reserved